Abstract 566P
Background
The incidence of lower gastrointestinal tract (GI) cancers among adolescents and young adults (AYAs) is rising. A cancer diagnosis and treatment(s) can lead to long-term morbidity and disrupt physical, cognitive, and psychosocial development, which can result in a reduced health-related quality of life (HRQOL) in this young population. The aim of this study was to describe the long-term survivorship outcomes of AYA with lower GI cancer.
Methods
The Netherlands Cancer Registry identified AYA cancer survivors (aged 18-39 years at initial cancer diagnosis, 5-20 years past diagnosis). They were invited to participate in a population-based, cross-sectional questionnaire study (SURVAYA). Survivorship issues (EORTC QLQ-SURV111) and HRQOL (EORTC QLQ-C30) were assessed. For this secondary analysis, we used data of all participating AYA colorectal and anal cancer patients.
Results
82 SURVAYA participants were selected (43% colon, 47% rectal and 8% anal cancer; 59% male sex; mean age 34 years at study participation; 11.3 years after diagnosis). Primary treatment consisted of surgery (18%); surgery and chemotherapy (23%); surgery and radiotherapy (10%); radiotherapy and chemotherapy (10%); surgery, radiotherapy and chemotherapy (39%); 35% of patients had a stoma. AYA cancer survivors reported to some extent issues related to body image (41%), sexual intimacy (41%), fertility (49%), social isolation (43%), uncertainty about future (71%), reduced career opportunities (55%), reduced income (41%), and getting a mortgage/insurance (49%). Compared to the normative population, AYA cancer survivors experienced higher levels of fatigue (31.9 vs. 19.4), pain (15.4 vs. 11.4), insomnia (22.4 vs 17.3) and diarrhea (16.2 vs. 5.5); and reported lower physical (89.7 vs. 94.8), role (81.1 vs. 91.7), emotional (77.7 vs. 85.4), cognitive (80.0 vs. 92.0) and social functioning (85.3 vs. 93.6). Overall HRQOL was lower for AYAs compared to the norm (72.1 vs. 75.9; all p<0.05).
Conclusions
A substantial proportion of AYA lower GI cancer survivors reports long-term psychosocial and physical survivorship issues. Access to tailored age-specific healthcare resources is needed to maximize their HRQOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute.
Funding
Netherlands Organization for Scientific Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Presenter: Marcel Reiser
Session: Poster session 10
623P - VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Presenter: Yijiao Chen
Session: Poster session 10
624P - Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
Presenter: Meng Qiu
Session: Poster session 10
625P - Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Presenter: Claire Gallois
Session: Poster session 10
626P - Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Presenter: Francisco Javier Ros Montana
Session: Poster session 10